ArticleClinicoEconomics and outcomes research : CEOR2022

Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age <65 with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction: A Cost-Benefit Analysis.

Sarah Glover et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.